Human Health before, during, and after COVID-19

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 3461

Special Issue Editor


E-Mail Website
Guest Editor
Respiratory Unit, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, Hospital Policlinico, Modena, Italy
Interests: COPD; dyspnea; frailty; ageing; COVID-19; asthma; interstitial lung disease; pleural disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It has been more than three years since COVID-19 was declared a global pandemic. Since that point, we have experienced profound changes in the ways that we work, socialise, and learn. The severity of this transformation has allowed us to examine daily practices, social norms, institutions, and the positive and negative aspects of our former lifestyles. The pandemic compelled us to appreciate the precious details of our lives that we have taken for granted: workplaces, human touch, parties, travel, and access to and the utilisation of healthcare facilities. We are thus able to reflect on the ways we live now in order to modify our cultures and find different ways to improve the quality of life for future generations. Many trends that had already started before COVID-19 have been accelerated by the impact of the pandemic. Examples include the digital economy, with the rise of telemedicine in the healthcare delivery services.

One of the hardest things to deal with in this period was maintaining physical distance. Physical interactions are an essential part of human social experience, and they are particularly important for the development of young people. Social distancing, school closures, and physical isolation from friends have been especially challenging for adolescents. Some have subsequently experienced feelings of loneliness, hopelessness, and sadness. Remote learning and homeworking under lockdown have also impacted the wellbeing of university students and young workers. Over the course of the pandemic, people of all ages reported symptoms consistent with anxiety and depression, regardless of severity of any viral infection. Additionally, increasing evidence of post-COVID long-term effects has been reported in the literature. Long COVID describes a range of symptoms, including fatigue, dyspnea, brain fog, and mental health disorders.

COVID is becoming endemic, which means that we will live with it as we do with the flu, i.e., without consequences as severe as those seen in the first three years. However, while some countries have reported a decline in COVID-19 cases and deaths, largely due to high vaccination coverage, there is still a relevant public health concern about refugees and unvaccinated people in many developing countries. The behaviour we all exhibit and the epidemiology of the virus itself are extremely important. New SARS-CoV-2 variants show increasing levels of concern and are likely to impact the epidemiological situation worldwide.

This Special Issue aims to provide a collection of high-quality data and new insights into COVID-19. We invite healthcare professionals and researchers involved in COVID-19 to submit original research articles or reviews to Life. Papers will be peer-reviewed by experts in the field.

You may choose our Joint Special Issue in Healthcare.

Dr. Alessia Verduri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • telemedicine
  • pandemic-related anxiety
  • pandemic-related depression
  • long COVID
  • unvaccinated people
  • new SARS-CoV-2 variants

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 795 KiB  
Article
Assessing the Association between Biomarkers and COVID-19 Mortality Using the Joint Modelling Approach
by Matteo Di Maso, Serena Delbue, Maurizio Sampietro, Monica Ferraroni, Annalisa Modenese, Maria Dolci, Federico Ambrogi and Pasquale Ferrante
Life 2024, 14(3), 343; https://doi.org/10.3390/life14030343 - 06 Mar 2024
Viewed by 709
Abstract
We evaluated the association between biomarkers and COVID-19 mortality. Baseline characteristics of 403 COVID-19 patients included sex and age; biomarkers, measured throughout the follow-up, included lymphocytes, neutrophils, ferritin, C-reactive protein, glucose, and LDH. Hazard ratios (HRs) and corresponding 95% credible intervals (CIs) were [...] Read more.
We evaluated the association between biomarkers and COVID-19 mortality. Baseline characteristics of 403 COVID-19 patients included sex and age; biomarkers, measured throughout the follow-up, included lymphocytes, neutrophils, ferritin, C-reactive protein, glucose, and LDH. Hazard ratios (HRs) and corresponding 95% credible intervals (CIs) were estimated through joint models (JMs) using a Bayesian approach. We fitted univariable (a single biomarker) and multivariable (all biomarkers) JMs. In univariable analyses, all biomarkers were significantly associated with COVID-19 mortality. In multivariable analysis, HRs were 1.78 (95% CI: 1.13–2.87) with a doubling of neutrophils levels, 1.49 (95% CI: 1.19–1.95) with a doubling of C-reactive protein levels, 2.66 (95% CI: 1.45–4.95) for an increase of 100 mg/dL of glucose, and 1.31 (95% CI: 1.12–1.55) for an increase of 100 U/L of LDH. No evidence of association was observed for lymphocytes and ferritin in multivariable analysis. Men had a higher COVID-19 mortality risk than women (HR = 1.75; 95% CI: 1.07–2.80) and age showed the strongest effect with a rapid increase from 60 years. These findings using JM confirm the usefulness of biomarkers in assessing COVID-19 severity and mortality. Monitoring trend patterns of such biomarkers can provide additional help in tailoring the appropriate care pathway. Full article
(This article belongs to the Special Issue Human Health before, during, and after COVID-19)
Show Figures

Figure 1

Review

Jump to: Research, Other

13 pages, 509 KiB  
Review
Acute Myocardial Infarction during the COVID-19 Pandemic: Long-Term Outcomes and Prognosis—A Systematic Review
by Marius Rus, Adriana Ioana Ardelean, Felicia Liana Andronie-Cioara and Georgiana Carmen Filimon
Life 2024, 14(2), 202; https://doi.org/10.3390/life14020202 - 31 Jan 2024
Cited by 2 | Viewed by 1212
Abstract
Coronavirus disease 2019 (COVID-19) was a global pandemic with high mortality and morbidity that led to an increased health burden all over the world. Although the virus mostly affects the pulmonary tract, cardiovascular implications are often observed among COVID-19 patients and are predictive [...] Read more.
Coronavirus disease 2019 (COVID-19) was a global pandemic with high mortality and morbidity that led to an increased health burden all over the world. Although the virus mostly affects the pulmonary tract, cardiovascular implications are often observed among COVID-19 patients and are predictive of poor outcomes. Increased values of myocardial biomarkers such as troponin I or NT-proBNP were proven to be risk factors for respiratory failure. Although the risk of acute coronary syndromes (ACSs) was greater in the acute phase of COVID-19, there were lower rates of hospitalization for ACSs, due to patients’ hesitation in presenting at the hospital. Hospitalized ACSs patients with COVID-19 infection had a prolonged symptom-to-first-medical-contact time, and longer door-to-balloon time. The mechanisms of myocardial injury in COVID-19 patients are still not entirely clear; however, the most frequently implicated factors include the downregulation of ACE2 receptors, endothelial dysfunction, pro-coagulant status, and increased levels of pro-inflammatory cytokines. The aim of this paper is to evaluate the long-term outcomes and prognosis of COVID-19 survivors that presented an acute myocardial infarction, by reviewing existing data. The importance of the association between this infectious disease and myocardial infarction arises from the increased mortality of patients with SARS-CoV-2 infection and AMI (10–76%, compared with 4.6% for NSTEMI patients and 7% for STEMI patients without COVID-19). The literature review showed an increased risk of cardiovascular events in COVID-19 survivors compared with the general population, even after the acute phase of the disease, with poorer long-term outcomes. Full article
(This article belongs to the Special Issue Human Health before, during, and after COVID-19)
Show Figures

Graphical abstract

Other

Jump to: Research, Review

20 pages, 829 KiB  
Systematic Review
Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review
by Bing-Qi Wu, De-Yi Liu, Te-Chun Shen, Yu-Ru Lai, Tsai-Ling Yu, Hsiang-Li Hsu, Hsiu-Ming Lee, Wei-Chih Liao and Te-Chun Hsia
Life 2024, 14(4), 438; https://doi.org/10.3390/life14040438 - 26 Mar 2024
Viewed by 949
Abstract
The coronavirus disease (COVID-19) pandemic has resulted in an increasing population that is experiencing a wide range of long-lasting symptoms after recovery from the acute infection. Long COVID refers to this specific condition and is associated with diverse symptoms, such as fatigue, myalgias, [...] Read more.
The coronavirus disease (COVID-19) pandemic has resulted in an increasing population that is experiencing a wide range of long-lasting symptoms after recovery from the acute infection. Long COVID refers to this specific condition and is associated with diverse symptoms, such as fatigue, myalgias, dyspnea, headache, cognitive impairment, neurodegenerative symptoms, anxiety, depression, and a sense of despair. The potential of hyperbaric oxygen therapy (HBOT) to improve chronic fatigue, cognitive impairments, and neurological disorders has been established; therefore, the use of HBOT to treat long COVID has also been studied. We conducted a literature search between 1 January 2019 and 30 October 2023, focusing on the clinical efficacy and utility of HBOT for treating long COVID and found ten clinical studies that fit the review topic, including one case report, five one-group pretest-posttest design studies, one safety report from a randomized controlled trial (RCT), and three complete reports of RCTs. Most studies found that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms, and cardiopulmonary function. Although HBOT has shown some benefits for long COVID symptoms, further rigorous large-scale RCTs are required to establish precise indications, protocols, and post-treatment evaluations. Full article
(This article belongs to the Special Issue Human Health before, during, and after COVID-19)
Show Figures

Figure 1

Back to TopTop